

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Palopegteriparatide for treating hypoparathyroidism ID6380

Provisional Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
Company	General
Ascendis Pharma	All Wales Therapeutics and Toxicology
(palopegteriparatide)	Centre
	 Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Amend	Wales
Butterfly Thyroid Cancer Trust	British National Formulary
British Thyroid Foundation	Care Quality Commission
Parathyroid UK	Department of Health, Social Services
 South Asian Health Foundation 	and Public Safety for Northern Ireland
Specialised Healthcare Alliance	Healthcare Improvement Scotland
Thyroid UK	Medicines and Healthcare products
	Regulatory Agency
Healthcare professional groups	 National Association of Primary Care
 Association of Anaesthetists 	 National Pharmacy Association
 Association of Surgeons of Great 	NHS Confederation
Britain and Ireland	Scottish Medicines Consortium
 British Association of Endocrine and 	Welsh Government
Thyroid Surgeons	Welsh Health Specialised Services
British Association of Surgical	Committee
Oncology	
British Geriatrics Society	Possible comparator companies
 British Society for Haematology 	AAH Pharmaceuticals (alfacalcidol,
British Thyroid Association	calcitriol, calcium carbonate, calcium
 Royal College of Anaesthetists 	gluconate)
 Royal College of General Practitioners 	Accord Healthcare UK (calcium
 Royal College of Nursing 	carbonate, calcium gluconate)
 Royal College of Pathologists 	Alliance Healthcare (alfacalcidol,
 Royal College of Physicians 	calcitriol)
 Royal College of Radiologists 	Atnahs Pharma UK (calcitriol)
 Royal College of Surgeons 	B.Braun Medical (calcium gluconate)
 Royal Pharmaceutical Society 	Crescent Pharma (alfacalcidol)
 Royal Society of Medicine 	Essential Healthcare (alfacalcidol,
 UK Clinical Pharmacy Association 	calcium carbonate)
	Forum Health Products (calcium
<u>Others</u>	carbonate)
Department of Health and Social Care	Galderma UK (calcitriol)

Provisional stakeholder list for the evaluation of palopegteriparatide for treating hypoparathyroidism ID6380


Issue date: March 2024



Consultees	Commentators (no right to submit or appeal)
NHS England	 Galen (calcium carbonate) Grunenthal (calcium carbonate) Haleon UK (calcium carbonate) HealthAid (calcium carbonate) Hameln Pharma (calcium gluconate) Internis Pharmaceuticals (calcium carbonate) Mylan (calcium carbonate) Kyowa Kirin (calcium carbonate) Medihealth Northern (alfacalcidol, calcitriol) Neon Healthcare (alfacalcidol, calcium carbonate) Phoenix Healthcare Distribution (alfacalcidol, calcitriol, calcium carbonate) Roche Products (calcitriol) Sandoz (calcium carbonate) Sigma Pharmaceuticals (alfacalcidol, calcitriol) Stirling Anglian Pharmaceuticals (calcium carbonate) Strides Pharma (alfacalcidol) Takeda UK (calcium carbonate, recombinant human parathyroid hormone) Teva UK (calcitriol) Theramex (alfacalcidol, calcium TriOn Pharma (alfacalcidol, calcium
	Relevant research groups Cochrane Metabolic & Endocrine Disorders Group Cochrane Haematology Cochrane UK Genomics England MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

Provisional stakeholder list for the evaluation of palopegteriparatide for treating hypoparathyroidism ID6380

Issue date: March 2024



NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.